Ying Liu

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Akeso (Hong Kong Stock Exchange code: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$1.9 billion (approximately US$250 million) follow-on public offering.

Cooley advised YH Entertainment, an established artist management company in China, on its HK$490 million ($63 million) global offering.

Cooley advised TI Cloud on its $71.7 million initial public offering of 43,530,000 shares at a public offering price of HK$12.85 per share. TI Cloud offers a broad array of cloud-native customer contact solutions that enable enterprises to engage in multichannel customer interactions. Partners Michael Yu and Will Cai led the Cooley team.